The future of cell therapy manufacturing has arrived

Cell therapy development and approval rates have experienced unprecedented growth since the FDA approval of Kymriah in 2017. Today there are six approved cell therapies on the market. With more than 2,800 cell therapies in development, the pace of regulatory approvals is expected to increase dramatically.

While the recent pace of newly approved therapies is promising for patients, conventional CDMOs are unable to scale and meet total patient demand due to the lack of automated, high-throughput manufacturing technologies. Consequently, patients are dying while waiting for their life-saving treatments.

In this webinar, Fabian Gerlinghaus, CEO & Co-founder of Cellares, will unveil a new paradigm for mass manufacturing the personalized living drugs of the 21st century. Mr. Gerlinghaus will share how Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will overcome the limitations of conventional CDMOs and accelerate access to life-saving cell therapies for patients through:

  • A global network of IDMO Smart Factories, which produce ten times more cell therapy batches using the same footprint and workforce as conventional CDMO facilities
  • Reduction of manufacturing costs and process failure rates through closed and fully automated end-to-end manufacturing
  • Integrated, high-throughput technologies for cell therapy manufacturing and in-process QC
watch now
Watch the webinar on demand
Fabian Gerlinghaus

Fabian Gerlinghaus

Co-Founder & CEO, Cellares

Fabian Gerlinghaus is Co-Founder and Chief Executive Officer of Cellares. He is driven by a strong sense of purpose and is passionate about meeting total patient demand for cell therapies globally. With 10+ years of experience as an innovator and a leader, Fabian has established a track record of assembling top-performing teams to successfully drive novel bioprocessing technologies from ideation to commercial readiness. Prior to co-founding Cellares, Fabian served as Chief Innovation Officer at Synthego, where he co-invented the company’s proprietary RNA synthesizer technology and helped grow the company from five to more than 230 employees. He successfully led the interdisciplinary team that took synthesizer technology from whiteboard sketch to production-ready instruments within two years, enabling the company to be the first to market with its CRISPR/Cas9 product portfolio. He earned a master’s degree in aerospace engineering from the Technical University of Munich, and an honors degree in technology management from the Center for Digital Technology and Management, Munich.

Surani Fernando

Surani Fernando


Surani Fernando is a seasoned healthcare journalist and editor with over 13 years experience covering the biopharma industry. A Sydney native, she started her investigative journalism career in London covering clinical trials, M&A and financing deals for BioPharm Insight, later moving to New York to continue her work as an enterprise journalist and editorial leader for GlobalData and Reorg. She is now based in Madrid working as a freelance journalist, consultant writer and podcast producer.